Clinical Trial Update: Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients

View source ↗

Summary

A clinical trial from the Medical University of Vienna is evaluating Torque Teno Virus as a biomarker to predict response to immune checkpoint inhibitor therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Immune checkpoint inhibitors (immune checkpoint inhibitor)

Snippet

Sponsor: Medical University of Vienna | Conditions: NSCLC (Non-small Cell Lung Cancer) | Status: RECRUITING